RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $76 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams reiterates an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintains a $76 price target.
June 22, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital reiterates an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintains a $76 price target.
The reiteration of an Outperform rating by RBC Capital's analyst Brian Abrahams indicates a positive outlook for Intra-Cellular Therapies. The maintained $76 price target suggests potential upside for the stock, which could lead to short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100